1 / 40

Insights into Global Generic Market Strategy

Delve into the evolving landscape of the global generic market, exploring key trends, niches, and competition dynamics. Learn about the impact of patent expiries, market share shifts, and the profitability of generic brands. Discover top companies and their strategies in this dynamic marketplace.

tierram
Download Presentation

Insights into Global Generic Market Strategy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Generics & Companies Chesapeake Dr. Brian W Tempest www.briantempest.com brian.tempest@clara.co.uk UK March 2014

  2. 3. Global Generic Marketplace

  3. Patent Thickets (for Perindopril)

  4. Branded Generics • Promotion to doctors rather than pharmacists • Relevant to Central Europe, East Europe, Latam, Asia • Consistent sales year on year • No huge highs & lows for sales and profits • Need field force to promote products • Tend to be profitable • Promoted in conventional manner • Global generic brands

  5. Niches • Injectables • OTC - brands last forever • NDDS - once a day technology • Difficult Chemistry - hormones, penems, peptides • Natural Products • Fermentation technology • Aerosols • Implants • Patches • Branded generics • Biosimilars • Para 4 180 days USA exclusivity/first day EU launches

  6. Generic Global Volume Share Source: Sandoz

  7. Generics 35% Premium over last 10yearsSource: Societe Generale June 2013

  8. Generics versus Big Pharma

  9. Generic Profit Margin Profile in descending order source: Deutsche Bank July 2010

  10. Molecules - Cost of developmentsource: Societe Generale

  11. Global Pharma Market Size

  12. Global Pharma Spending 2011 to 2016source: IMS 17 June 2013, Brand/Generic//Other

  13. 66 Cos received WLs between 2010 and June 2013 with 8 from India source: Daily Mail 13 October 2013

  14. Generics - Rising Risk & Competition

  15. Patent Expiries to 2018source: EvaluatePharma 2012

  16. Products Going Off Patent in 2015 $33bSource: Evaluate Pharma 14 February 2013

  17. Counterfeit Medicines source WHO fact sheet N275; India level at 3% Source IPF-WHO

  18. Generic Cos by Sales over last Decade source: Citi Research August 2013

  19. Generic Cos – Operating Cash Flow source: Citi Research August 2013

  20. 4. Global Generic Companies

  21. Top 21 Global Generic Companies Source 8 June 2012 Generics Bulletin 8/21

  22. Next 26 Global Generic Companies Source 8 June 2012 Generics Bulletin 8/26

  23. The Teva Future – Standing StillSource: RBC Capital 12 December 2012

  24. Teva Losing Control of Costs in the EUsource: Teva June 2012

  25. Sandoz Sales 2012source: Novartis, Generics Bulletin June 7 2013

  26. Actavis Sales MomentumSource: RBC 12 March 2013

  27. Actavis Sales MomentumSource: RBC 12 March 2013

  28. Actavis R&D Assetssource: Actavis Promotional Material before Warner Chilcott acquisition

  29. Actavis Manufacturing Assetssource: Actavis Promotional Material before Warner Chilcott acquisition

  30. Global footprint of Watson/Actavis

  31. Cash Acquisitions vs free cash flowsource: FT 19 February 2014

  32. Actavis is favoured by Investorssource: Daily Finance 21 January 2014

  33. Mylan Sales MomentumSource: RBC 12 March 2013

  34. Mylan Sales MomentumSource: RBC 12 March 2013

  35. Mylan acquires 9 plants source: FiercePharma February 2014

  36. Stada focus on RussiaSource: Stada

  37. Stadasource: Jefferies March 2014

  38. Stadasource: Jefferies March 2014

  39. Sanofi Generics 2012Source: Generics bulletin 15 February 2013

  40. Thank You brian.tempest@clara.co.uk www.briantempest.com

More Related